2023
Use of Immersive Virtual Reality Spaces to Engage Adolescent and Young Adult Patients With Cancer in Therapist-Guided Support Groups: Protocol for a Pre-Post Study
Marks A, Garbatini A, Hieftje K, Puthenpura V, Weser V, Fernandes C. Use of Immersive Virtual Reality Spaces to Engage Adolescent and Young Adult Patients With Cancer in Therapist-Guided Support Groups: Protocol for a Pre-Post Study. JMIR Research Protocols 2023, 12: e48761. PMID: 37943596, PMCID: PMC10667982, DOI: 10.2196/48761.Peer-Reviewed Original ResearchINTERNATIONAL REGISTERED REPORT IDENTIFIERYoung adult patientsSupport groupsAdult patientsYoung adultsMean attendance rateSupport group interventionNon-Hispanic blacksNon-Hispanic whitesOverall retention rateNon-Hispanic AsiansRare disease populationPeer support groupsFacilitated support groupBone marrow failureMedian ageCommon diagnosisPreliminary efficacyHematologic malignanciesDisease populationLife measuresPatientsFinal intervention sessionTransgender femalesPsychosocial supportOUTC-08. IMPLEMENTING SOCIAL DETERMINANT OF HEALTH DATA COLLECTION FOR PEDIATRIC, ADOLESCENT AND YOUNG ADULT NEURO-ONCOLOGY PATIENTS IN THE CLINICAL TRIAL CONSORTIA SETTING: PROGRESS AND CHALLENGES
Puthenpura V, Bona K, Cooney T, Coven S, Davidson T, Fouladi M, Kline C, Leary S, Mueller S, Green A, Marks A. OUTC-08. IMPLEMENTING SOCIAL DETERMINANT OF HEALTH DATA COLLECTION FOR PEDIATRIC, ADOLESCENT AND YOUNG ADULT NEURO-ONCOLOGY PATIENTS IN THE CLINICAL TRIAL CONSORTIA SETTING: PROGRESS AND CHALLENGES. Neuro-Oncology 2023, 25: i37-i37. PMCID: PMC10260067, DOI: 10.1093/neuonc/noad073.145.Peer-Reviewed Original ResearchNeuro-oncology patientsMulticenter clinical trialClinical trialsSocial determinantsSocioeconomic statusClinical Trials ConsortiumLong-term complicationsAYA cancer patientsAdverse social determinantsSocioeconomic status dataAdverse SDOHSurvival disparitiesMultidisciplinary careTherapy adherenceToxicity incidenceCancer patientsTrial therapyPersonal socioeconomic statusOutcome disparitiesTrial designSDOHPatientsHealth equityHealth data collectionTrialsAdjuvant chemotherapy does not improve outcome in children with ovarian immature teratoma: A comparative analysis of clinical trial data from the Malignant Germ Cell International Consortium
Vieira A, Puthenpura V, Krailo M, Fallahazad N, Brougham M, Murray M, Frazier A, Lopes L, Pashankar F. Adjuvant chemotherapy does not improve outcome in children with ovarian immature teratoma: A comparative analysis of clinical trial data from the Malignant Germ Cell International Consortium. Pediatric Blood & Cancer 2023, 70: e30426. PMID: 37243320, DOI: 10.1002/pbc.30426.Peer-Reviewed Original ResearchConceptsOvarian immature teratomaOverall survivalImmature teratomaPostoperative chemotherapyBrazilian patientsStage IIAdjuvant chemotherapyUK cohortGrade 1 diseaseGrade 3 patientsReceipt of chemotherapyMainstay of therapyValue of chemotherapyPrimary outcome measureClinical trial dataIT patientsEntire cohortUK patientsRelapse riskBrazilian cohortOutcome measuresPractice variationChemotherapyPatientsStage I
2021
Association of Medicare and Medicaid Insurance Status with Increased Spine Surgery Utilization Rates
Benton J, Weiss B, Mowrey W, Yassari N, Wang B, De La Garza Ramos R, Gelfand Y, Castro-Rivas E, Puthenpura V, Yassari R, Yanamadala V. Association of Medicare and Medicaid Insurance Status with Increased Spine Surgery Utilization Rates. Spine 2021, 46: e939-e944. PMID: 33496542, DOI: 10.1097/brs.0000000000003968.Peer-Reviewed Original ResearchConceptsInsurance statusSpine surgeryMedicaid patientsSpine careRetrospective single-institution studyPrivate insuranceLogistic regressionMedicaid insurance statusMultivariable logistic regressionSingle-institution studyMultivariate logistic regressionPatient insurance statusConsecutive outpatientsTreatment recommendationsUninsured patientsWorse outcomesBACKGROUND DATAInclusion criteriaPatient's conditionPatientsSurgerySpine surgeonsNeurosurgical clinicSignificant associationSpine interventions
2016
Delayed methimazole-induced agranulocytosis in a 6-year old patient with Graves’ disease
Puthenpura V, Desai K, Bauer A, Marshall I. Delayed methimazole-induced agranulocytosis in a 6-year old patient with Graves’ disease. International Journal Of Pediatric Endocrinology 2016, 2016: 16. PMID: 27605984, PMCID: PMC5013617, DOI: 10.1186/s13633-016-0034-6.Peer-Reviewed Original ResearchOlder patientsMMI therapySide effectsMethimazole-induced agranulocytosisMonths of treatmentRare side effectSerious side effectsDose-dependent mannerMethimazole therapyPediatric GravesCase presentationWeDisease populationUnusual casePatientsInconclusive dataTherapyAgranulocytosisDependent mannerTypical timelineMonthsGravesIncidenceConclusionsThisDiseaseRecurrent Thyrotoxicosis due to Both Graves’ Disease and Hashimoto’s Thyroiditis in the Same Three Patients
Schaffer A, Puthenpura V, Marshall I. Recurrent Thyrotoxicosis due to Both Graves’ Disease and Hashimoto’s Thyroiditis in the Same Three Patients. Case Reports In Endocrinology 2016, 2016: 6210493. PMID: 27340576, PMCID: PMC4906178, DOI: 10.1155/2016/6210493.Peer-Reviewed Original ResearchGraves' diseaseHashimoto's thyroiditisDisease processRecurrence of thyrotoxicosisAutoimmune disease processSeparate disease processesAntithyroid medicationRadioablation therapyRecurrent thyrotoxicosisThree patientsInitial presentationCase reportThyrotoxicosisThyroiditisThyroid glandDiseaseUnique genetic differencesMonozygotic twinsPatientsTemporary resolutionHashitoxicosisMedicationsRecurrenceTherapySpinal cord glioblastoma: 25years of experience from a single institution
Yanamadala V, Koffie R, Shankar G, Kumar J, Buchlak Q, Puthenpura V, Frosch M, Gudewicz T, Borges L, Shin J. Spinal cord glioblastoma: 25years of experience from a single institution. Journal Of Clinical Neuroscience 2016, 27: 138-141. PMID: 26755453, DOI: 10.1016/j.jocn.2015.11.011.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedChemoradiotherapyCombined Modality TherapyDNA MethylationFemaleGlioblastomaHumansKarnofsky Performance StatusMaleMiddle AgedNeoplasm ProteinsNeoplasm Recurrence, LocalProto-Oncogene Proteins B-rafRecovery of FunctionSpinal Cord NeoplasmsSurvival AnalysisTreatment OutcomeTumor Suppressor Protein p53ConceptsHigh-grade spinal cord gliomasSpinal cord gliomasKarnofsky performance statusFunctional statusAmerican Spine Injury Association (ASIA) scorePost-operative functional statusPost-operative radiationSubtotal surgical resectionSubset of patientsTumor recurrence rateYear survival rateTargeted molecular therapiesHigh-grade gliomasAdjuvant chemotherapyPerformance statusSurgical resectionPrimary outcomeRecurrence rateSingle institutionExcellent survivalSpinal cordPatientsAssociation scoreGrade gliomasSurvival rate